Psoralidin acts as a dual protease inhibitor against PLpro and Mpro of SARS-CoV-2

Aditya Trivedi, Tushar Kushwaha,  Ishani, Sudhanshu Vrati, Dharmender Gupta, Sarala Rani Kayampeta, Mohammad Khalid Parvez, Krishna Kishore Inampudi, Mohan Babu Appaiahgari, Deepak Sehgal
{"title":"Psoralidin acts as a dual protease inhibitor against PLpro and Mpro of SARS-CoV-2","authors":"Aditya Trivedi,&nbsp;Tushar Kushwaha,&nbsp; Ishani,&nbsp;Sudhanshu Vrati,&nbsp;Dharmender Gupta,&nbsp;Sarala Rani Kayampeta,&nbsp;Mohammad Khalid Parvez,&nbsp;Krishna Kishore Inampudi,&nbsp;Mohan Babu Appaiahgari,&nbsp;Deepak Sehgal","doi":"10.1111/febs.17380","DOIUrl":null,"url":null,"abstract":"<p>The emergence of new coronavirus variants and concerns about vaccine effectiveness against these novel variants emphasize the need for broad-spectrum therapeutics targeting conserved coronaviral non-structural proteins. Accordingly, a virtual library of 178 putative inhibitors targeting SARS-CoV-2 Papain-like protease (PL<sup>pro</sup>) was compiled through a systematic review of published literature and subsequently screened using molecular docking. Selected hits were analyzed for protease inhibitory activities, binding strength, and antiviral activities against HCoV229E-based surrogate system and subsequently against SARS-CoV-2 for validation. Differences in potential modes of action were investigated using an HCoV229E-based system, combined with <i>in silico</i> and biophysical methods against SARS-CoV-2 system. Of the 178 hits, 13 molecules showed superior docking scores against PL<sup>pro</sup> and met the inclusion criteria for further investigations. Of these, seven showed notable inhibitory activities against PL<sup>pro</sup>. Particularly, both Psoralidin and Corylifol-A exhibited superior and, importantly, dual activities against SARS-CoV-2 M<sup>pro</sup>. Both molecules were found to be biologically active against HCoV229E and SARS-CoV-2; however, Psoralidin exhibited more consistent effects and was relatively well-tolerated. Detailed <i>in silico</i> analyses of their interactions with the two proteases identified differences in their modes of action, primarily due to differences in their binding of PL<sup>pro</sup>. Based on these findings, we propose Psoralidin as a potential candidate for further development as a broad-spectrum antiviral and Corylifol-A as an ideal candidate for lead optimization.</p>","PeriodicalId":94226,"journal":{"name":"The FEBS journal","volume":"292 5","pages":"1106-1123"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The FEBS journal","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/febs.17380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The emergence of new coronavirus variants and concerns about vaccine effectiveness against these novel variants emphasize the need for broad-spectrum therapeutics targeting conserved coronaviral non-structural proteins. Accordingly, a virtual library of 178 putative inhibitors targeting SARS-CoV-2 Papain-like protease (PLpro) was compiled through a systematic review of published literature and subsequently screened using molecular docking. Selected hits were analyzed for protease inhibitory activities, binding strength, and antiviral activities against HCoV229E-based surrogate system and subsequently against SARS-CoV-2 for validation. Differences in potential modes of action were investigated using an HCoV229E-based system, combined with in silico and biophysical methods against SARS-CoV-2 system. Of the 178 hits, 13 molecules showed superior docking scores against PLpro and met the inclusion criteria for further investigations. Of these, seven showed notable inhibitory activities against PLpro. Particularly, both Psoralidin and Corylifol-A exhibited superior and, importantly, dual activities against SARS-CoV-2 Mpro. Both molecules were found to be biologically active against HCoV229E and SARS-CoV-2; however, Psoralidin exhibited more consistent effects and was relatively well-tolerated. Detailed in silico analyses of their interactions with the two proteases identified differences in their modes of action, primarily due to differences in their binding of PLpro. Based on these findings, we propose Psoralidin as a potential candidate for further development as a broad-spectrum antiviral and Corylifol-A as an ideal candidate for lead optimization.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
补骨脂素是一种双重蛋白酶抑制剂,可抑制SARS-CoV-2的PLpro和Mpro。
新型冠状病毒变异的出现以及对这些新变异疫苗有效性的担忧,强调需要针对保守的冠状病毒非结构蛋白的广谱治疗。因此,通过对已发表文献的系统回顾,编制了针对SARS-CoV-2木瓜蛋白酶(PLpro)的178个推定抑制剂的虚拟文库,并随后使用分子对接进行筛选。分析选定的命中点对基于hcov229的替代系统的蛋白酶抑制活性、结合强度和抗病毒活性,随后对SARS-CoV-2进行验证。采用基于hcov229的系统,结合计算机和生物物理方法对SARS-CoV-2系统的潜在作用方式进行了研究。在178个hit中,13个分子与PLpro的对接得分较高,符合进一步研究的纳入标准。其中7种对PLpro具有明显的抑制活性。特别是,Psoralidin和Corylifol-A对SARS-CoV-2 Mpro均表现出优越的双重活性。发现这两种分子对HCoV229E和SARS-CoV-2具有生物活性;然而,补骨脂素表现出更一致的效果,并且耐受性相对较好。它们与两种蛋白酶相互作用的详细计算机分析确定了它们的作用模式的差异,主要是由于它们与PLpro结合的差异。基于这些发现,我们建议Psoralidin作为进一步开发的广谱抗病毒药物的潜在候选者,而Corylifol-A作为先导物优化的理想候选者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Correction. Enhancing therapeutic efficacy through degradation of endogenous extracellular matrix in primary breast tumor spheroids. Potency of agarose gel-supported lipid bilayers for electrophysiologic analysis of channel pores formed by Bacillus thuringiensis insecticidal proteins. Tudor staphylococcal nuclease (Tudor-SN) regulates activation of quiescent hepatic stellate cells. Pharmacological manipulation of liver fibrosis progression using novel HDAC6 inhibitors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1